Citigroup Rates ResMed (RMD) buy, $270 Price Target

Citigroup maintains a Buy rating on ResMed with a $270 price target, a 43.14% upside from the current price.

By EarningsIQ Research Desk · Published Jun 16, 2026, 2:04 AM EDT · Updated Jun 22, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Citigroup rated ResMed Inc. ($RMD) "buy" with a $270 price target on June 15, 2026.

Since the rating, $RMD is down 2.2% after 1 week, up 3.0% after 1 month and up 24.3% to date (from the $192.19 close on Jun 15, 2026).

RMD ResMed Inc.

$238.97 -1.59% year to date

Daily close · Oct 16, 2026

Key Points

Citigroup reiterated its Buy rating on ResMed Inc. with a price target of $270 as of June 15, 2026.
Citigroup's $270 price target implies 43.14% upside from ResMed Inc.'s ($RMD) current $188.63 share price.
ResMed shares are trading around $194.78, with a market cap of $27.96 billion and a P/E ratio of 18.60.
Major institutional holders include BlackRock and Vanguard, with recent insider activity involving CEO Michael Farrell.

Get $RMD trade alerts by text

We text you when insiders, Congress or big funds trade $RMD. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ResMed Inc. alert may contain errors. Disclosures

Citigroup has reiterated its Buy rating on ResMed Inc. (NYSE: RMD), setting a price target of $270. This decision, announced on June 15, 2026, reflects Citigroup's continued confidence in ResMed's market position and growth potential.

ResMed Inc. Stock Down 16.2%

Shares of NYSE:RMD are currently trading near $194.78. ResMed has a market capitalization of approximately $27.96 billion. The company's P/E ratio stands at 18.60, while the forward P/E is 15.90. With a beta of 0.78, ResMed's stock has experienced a 52-week low of $180.27 and a high of $293.81. The stock's 50-day moving average is $209.32, and its 200-day moving average is $243.83. The company maintains a current ratio of 3.01 and a quick ratio of 2.00, with a debt-to-equity ratio of 12.99.

12-month forecast

$RMD price target

ResMed Inc. daily closes and this analyst's $270 target. Not advice.

Recent Earnings

In the most recent earnings report, ResMed posted revenue of approximately $5.54 billion, marking a growth of 10.8%. The company's net margin was 27.44%, and it achieved a return on equity of 25.25%. The next earnings announcement is scheduled for August 6, 2026.

Dividend

ResMed pays an annual dividend rate of $2.40, yielding 1.25%. The dividend payout ratio is 22.47%, indicating a balanced approach to returning capital to shareholders while reinvesting in growth.

Insider Buying and Selling at ResMed Inc.

Recent insider activity at ResMed includes several transactions by Chairman and CEO Michael Farrell. On June 8, 2026, Farrell sold 4,991 shares at an average price of $193.96 as a planned sale under Rule 10b5-1. On the same day, he also made an unplanned purchase of 4,991 shares at $146.34. Additionally, Global General Counsel Michael Rider sold 269 shares on June 1, 2026, at $190.57.

Analysts Set New Price Targets

On June 15, 2026, Citigroup maintained its Buy rating on ResMed with a $270 target. RBC Capital also kept a Buy rating with a target of $321 on May 1, 2026, while Wells Fargo maintained a Hold rating with a target of $227. The consensus among analysts is a Buy, with an average target price of $270.60 based on 15 opinions.

About ResMed Inc.

ResMed Inc., headquartered in San Diego, California, develops and markets medical devices and software for managing respiratory disorders. The company operates in two segments: Sleep and Breathing Health, and Residential Care Software. It provides solutions for sleep apnea, home medical equipment, and healthcare software services. Founded in 1989, ResMed employs around 10,600 people and is led by CEO Michael J. Farrell.

Bottom Line

Citigroup's reiterated Buy rating on ResMed highlights continued confidence in its market potential. With a $270 price target, the firm sees room for growth. ResMed's solid financial performance and strategic positioning in the healthcare sector make it a company to watch. Remember, 13F filings and analyst ratings are backward-looking and should be considered as part of a broader investment strategy.